X4 Pharmaceuticals Stock News

- CXCR4 antagonism proof of concept established, with 100% overall response rate to combination treatment in frontline and refractory patients -

- CXCR4 antagonism proof of concept established, with 100% overall response rate to combination treatment in frontline and refractory patients -

X4 Pharmaceuticals Inc. (NASDAQ:XFOR) concluded the trading at $3.56 on Friday, December 03 with a fall of -11.44% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $4.02 and 5Y monthly beta was reading 0.18 with its price kept floating in the X4 Pharmaceuticals Inc. (XFOR) Worth Considering For The Next Few Weeks Read More »

Company to present new clinical data supporting the expanded potential use of mavorixafor to treat a broad array of immunodeficiencies as well as new insights into WHIM syndrome

Company to present new clinical data supporting the expanded potential use of mavorixafor to treat a broad array of immunodeficiencies as well as new insights into WHIM syndrome

BOSTON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients w

Analysts expect X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) to announce earnings of ($0.68) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for X4 Pharmaceuticals earnings, with the highest EPS estimate coming in at ($0.47) and the lowest estimate coming in at ($0.82). X4 Pharmaceuticals reported earnings per share of ($0.91) in the []

Renaissance Technologies LLC decreased its position in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 16.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 130,694 shares of the companys stock after selling 25,350 shares during the period. Renaissance Technologies LLC owned approximately 0.53% of X4 []

Vanguard Group Inc. lifted its holdings in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 21.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 897,641 shares of the companys stock after purchasing an additional 161,039 shares during the period. Vanguard Group Inc. owned 3.61% of X4 Pharmaceuticals worth []

Zacks Investment Research downgraded shares of X4 Pharmaceuticals (NASDAQ:XFOR) from a hold rating to a sell rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of []

X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q3 2021 Results - Earnings Call Transcript

Earnings Call taking place at 9:05 a.m. ET expected to include discussion of abstracts accepted to the upcoming 63rd American Society of Hematology (ASH) Annual Meeting Earnings Call taking place at 9

Each brings significant experience in strategic marketing of rare disease therapeutics and commercial operations Each brings significant experience in strategic marketing of rare disease therapeutics

BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXC

BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from